Capricor Therapeutics Schedules Q1 2026 Earnings and Corporate Update
Event summary
- Capricor Therapeutics will release Q1 2026 financial results on May 12, 2026, after market close.
- Conference call and webcast scheduled for 4:30 p.m. ET on May 12, 2026.
- Deramiocel, the company's lead product candidate, is in late-stage development for Duchenne muscular dystrophy (DMD).
- Capricor has a commercialization agreement with Nippon Shinyaku for Deramiocel in the U.S. and Japan.
The big picture
Capricor Therapeutics is focusing on advancing its cell and exosome-based therapeutics, particularly Deramiocel for DMD, which is in late-stage development. The company's strategic partnership with Nippon Shinyaku for commercialization in the U.S. and Japan highlights its commitment to rare disease treatment. The upcoming earnings release and corporate update will provide insights into the company's financial health and progress in its clinical pipeline.
What we're watching
- Clinical Progress
- How the late-stage development of Deramiocel for DMD will impact Capricor's strategic positioning.
- Regulatory Approvals
- Whether Capricor can secure necessary regulatory approvals for Deramiocel in the U.S. and Japan.
- Financial Performance
- The pace at which Capricor can achieve product milestones and receive milestone payments from commercial partners.
Related topics